Dr. John Cush RheumNow
2 years 7 months ago
Mastery of knee arthrocentesis for internal medicine resident
Brian D. Jaros, MD, presents his poster at RWCS 2024.
https://t.co/xFoEGnj2QH https://t.co/DpW07jJTLf
A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.
A matched case–control study examined the electronic health records from the UK Clinical Practice Research Datalink and compared gout (one to five) with controls matched for age, sex, socioeconomic status, geographical region, and calendar, to look a the incidence of 12 cardiovascular diseases.
Dr. John Cush RheumNow
2 years 7 months ago
EGPA: Benralizumab (BEN) or Mepolizumab (MEP)
A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA.
https://t.co/1F8hBCOaFV https://t.co/smTSIY1HA3
Dr. John Cush RheumNow
2 years 7 months ago
Behçet’s Syndrome
A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches.
https://t.co/sLgoCRAavP https://t.co/NibyFpPzmW
Dr. John Cush RheumNow
2 years 7 months ago
Neonatal Fc receptor mAb (lowers Igs) development:
2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis
2023 FDA approved rozanolixizumab (Rystiggo) for MG
2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG
INTERESTING? https://t.co/Ou9An9EvUK https://t.co/XDDELNAYYD
The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis. A subsequent analysis of these patients showed several candidate biomarkers that may correlate with baseline and treatment‐associated changes in arterial inflammation in patients with RA.
Dr. John Cush RheumNow
2 years 7 months ago
PAPA (pyogenic arthritis, pyoderma gangrenosum & acne) syndrome is a hereditary autoinflammatory Dz caused by dominant mutation in PSTPIP1 (triggers IFN-γ-mediated pyrin induction & IL-18 release; can be Tx by JAK inhibition) https://t.co/fy0MnwDA5U https://t.co/l8n2EwgV0t
Dr. John Cush RheumNow
2 years 7 months ago
FDA approves 10th adalimumab biosimilar - called Simlandi (adalimumab-ryvk), from Alvotech and Teva. Unique in that it's the 1st high-concentration, citrate-free & interchangeable ADA biosimilar.https://t.co/V6zbCnpfvn https://t.co/igLddGMcoM
Dr. John Cush RheumNow
2 years 7 months ago
Norway study 1558 chart-reviewed SLE cases; 797 were new-onset SLE from 1999 to 2017. During this period the annual SLE incidence rates fell; mostly pronounced in women 50-59 yrs (fell 3.4 to 1.1 per 100K) - paralleled by 74% reduction menopausal HRT https://t.co/zYkXAnEcOI https://t.co/oaz9t65zZy
The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, particularly in the 5 to 10 years preceding the start of symptoms, finds research published in the open access journal RMD Open.
Dr. John Cush RheumNow
2 years 7 months ago
Australian study shows self-reported difficulties w/ ambulation (limited<=1 km) had a higher risk of hip and spinal fractures (32% to 219% more)/ Included 239 000 adults >45 yrs https://t.co/IWvKmPc2t8 https://t.co/CDYDzhMUoa
Dr. John Cush RheumNow
2 years 7 months ago
When Meningitis Strikes Twice
Amanda Moyer, MD, presents her poster at RWCS 2024.
https://t.co/er2E2XnrZZ https://t.co/vwDopOLPRH
Dr. John Cush RheumNow
2 years 7 months ago
With New Medications Come New Myopathies
Alexia Hwang, MD, presents her poster at RWCS 2024.
https://t.co/BjYxKk2QlW https://t.co/vDA0dllMQz
Dr. John Cush RheumNow
2 years 7 months ago
Immunosuppression Increasing
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on https://t.co/V10S4oVFsv; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.
https://t.co/KvZIiKowox https://t.co/cbBYydVQbB
